BriaCell Therapeutics (NASDAQ:BCTX – Get Rating) and Ovid Therapeutics (NASDAQ:OVID – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.
Valuation and Earnings
This table compares BriaCell Therapeutics and Ovid Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ovid Therapeutics||$208.38 million||0.73||$122.83 million||($0.99)||-2.19|
Ovid Therapeutics has higher revenue and earnings than BriaCell Therapeutics.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
BriaCell Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for BriaCell Therapeutics and Ovid Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BriaCell Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 200.84%. Ovid Therapeutics has a consensus target price of $2.50, indicating a potential upside of 15.21%. Given BriaCell Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe BriaCell Therapeutics is more favorable than Ovid Therapeutics.
Insider and Institutional Ownership
25.8% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 49.3% of Ovid Therapeutics shares are owned by institutional investors. 10.7% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
About Ovid Therapeutics
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.